BDKRB2 and infection: Further experiments on the B2R-antagonist effect on the SARS-CoV-2-infection of NHBE showed that pre-treatment with B2R-antagonist significantly reduced infection-mediated cytotoxicity measured by LDH release (Fig. 1F).